Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
New Disease-Modifying Therapies and New Challenges for MS.
Benign Multiple Sclerosis: Does it exist?
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Microvesicles: novel biomarkers for neurological disorders.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Lodonal/LDN
Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis.
Isolated trigeminal nerve palsy with motor involvement as a presenting manifestation of multiple sclerosis in an equatorial region - a case report.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.
Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Effects of Dalfampridine Extended-Release Tablets on 6-Minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning.
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis

Pages